High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort

Am J Gastroenterol. 2024 Aug 1;119(8):1624-1627. doi: 10.14309/ajg.0000000000002796. Epub 2024 Apr 8.

Abstract

Introduction: This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort.

Methods: The new MASLD/metabolic steatohepatitis nomenclature was applied to patients enrolled with pragmatic diagnoses of nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), and NASH cirrhosis and concordance were determined between the definitions.

Results: Approximately 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. Approximately 1,484/1,541 (96.3%, kappa 0.974) nonalcoholic fatty liver patients (metabolic dysfunction-associated steatotic liver), 2,195/2,201 (99.7%, kappa 0.998) NASH patients (metabolic steatohepatitis), and 1,999/2,003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.

Discussion: The new MASLD nomenclature is highly concordant with the previous TARGET-NASH pragmatic definitions.

MeSH terms

  • Adult
  • Aged
  • Cohort Studies
  • Fatty Liver / complications
  • Female
  • Humans
  • Liver Cirrhosis / complications
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease* / complications
  • Terminology as Topic
  • United States / epidemiology

Grants and funding